Anti-mutated KRAS T-Cell receptors - Kite Pharma
Alternative Names: anti-KRAS G12D mTCR PBL; anti-KRAS-G12D-mTCRLatest Information Update: 25 Oct 2021
At a glance
- Originator Kite Pharma; National Cancer Institute (USA)
- Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Gene transference; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Colorectal cancer